Incidence of COVID-19 mRNA vaccine symptomatic breakthrough infections during Omicron circulation in adults with or without infection prior to vaccination.

Autor: Durier C; INSERM US19, Villejuif, France. Electronic address: christine.durier@inserm.fr., Ninove L; Unité des Virus Émergents (UVE), Aix Marseille Univ, IRD 190, INSERM 1207, Marseille, France., van der Werf S; Institut Pasteur, Université Paris Cité, UMR 3569 CNRS, Unité de Génétique Moléculaire des Virus à ARN, Centre National de Référence Virus des Infections Respiratoires, Paris, France., Lefebvre M; Service de maladies infectieuses et tropicales, Centre de prévention des maladies infectieuses et transmissibles CHU de Nantes - CIC1413 Nantes, Nantes, France., Desaint C; INSERM US19, Villejuif, France; INSERM CIC 1417 Cochin Pasteur, Assistance Publique Hôpitaux de Paris, Hôpital Cochin, Innovative Clinical Research Network in Vaccinology, Université de Paris, Sorbonne Paris Cité, Paris, France., Bauer R; INSERM US19, Villejuif, France., Attia M; Institut Pasteur, Université Paris Cité, UMR 3569 CNRS, Unité de Génétique Moléculaire des Virus à ARN, Centre National de Référence Virus des Infections Respiratoires, Paris, France., Lecompte AS; Service de maladies infectieuses et tropicales, Centre de prévention des maladies infectieuses et transmissibles CHU de Nantes - CIC1413 Nantes, Nantes, France., Lachatre M; INSERM CIC 1417 Cochin Pasteur, Assistance Publique Hôpitaux de Paris, Hôpital Cochin, Innovative Clinical Research Network in Vaccinology, Université de Paris, Sorbonne Paris Cité, Paris, France., Maakaroun-Vermesse Z; Centre de Vaccination CHU de Tours, Centre d'Investigation Clinique CIC 1415, INSERM, CHRU de Tours, Tours, France., Nicolas JF; Centre International de Recherche en Infectiologie (CIRI), INSERM U1111, Université Claude Bernard Lyon I, Lyon, France; CHU Lyon-Sud, Pierre-Bénite, France., Verdon R; Service de Maladies Infectieuses, CHU de Caen, Dynamicure INSERM, UMR 1311, Normandie Univ, UNICAEN, Caen, France., Kiladjian JJ; AP-HP, Hôpital Saint-Louis, Centre d'Investigations Cliniques, INSERM, CIC1427, Université Paris Cité, Paris, France., Loubet P; VBMI, INSERM U1047, Department of Infectious and Tropical Diseases, Université de Montpellier, CHU Nîmes, Montpellier, France., Schmidt-Mutter C; INSERM CIC 1434, CHU Strasbourg, Strasbourg, France., Corbin V; CHU Clermont-Ferrand, INSERM CIC1405, Clermont-Ferrand, France., Ansart S; INSERM CIC 1412, CHU Brest, Brest, France., Melica G; Service d'Immunologie Clinique et Maladies Infectieuses, APHP, Hôpital Henri Mondor, INSERM CIC 1430, Créteil, France., Resch M; INSERM US19, Villejuif, France., Netzer E; INSERM US19, Villejuif, France., Kherabi Y; INSERM CIC 1417 Cochin Pasteur, Assistance Publique Hôpitaux de Paris, Hôpital Cochin, Innovative Clinical Research Network in Vaccinology, Université de Paris, Sorbonne Paris Cité, Paris, France., Tardieu R; ANRS Emerging Infectious Diseases, Paris, France., Lelièvre JD; INSERM U955, Vaccine Research Institute, Créteil, France., Tartour E; APHP, Hôpital Européen Georges Pompidou, INSERM U970, PARCC, Université de Paris, Paris, France., Meyer L; INSERM US19, Villejuif, France; INSERM, CESP U1018, Université Paris Saclay, APHP, Le Kremlin-Bicêtre, France., de Lamballerie X; Unité des Virus Émergents (UVE), Aix Marseille Univ, IRD 190, INSERM 1207, Marseille, France., Launay O; INSERM CIC 1417 Cochin Pasteur, Assistance Publique Hôpitaux de Paris, Hôpital Cochin, Innovative Clinical Research Network in Vaccinology, Université de Paris, Sorbonne Paris Cité, Paris, France.
Jazyk: angličtina
Zdroj: Infectious diseases now [Infect Dis Now] 2024 Aug; Vol. 54 (5), pp. 104886. Date of Electronic Publication: 2024 Mar 16.
DOI: 10.1016/j.idnow.2024.104886
Abstrakt: Objectives: COVID-19 vaccine breakthrough infections were frequently reported during circulation of the Omicron variant. The ANRS|MIE CoviCompareP study investigated these infections in adults vaccinated and boosted with BNT162b2 [Pfizer-BioNTech] and with/without SARS-CoV-2 infection before vaccination.
Methods: In the first half of 2021, healthy adults (aged 18-45, 65-74 and 75 or older) received either one dose of BNT162b2 (n = 120) if they had a documented history of SARS-CoV-2 infection at least five months previously, or two doses (n = 147) if they had no history confirmed by negative serological tests. A first booster dose was administered at least 6 months after the primary vaccination, and a second booster dose, if any, was reported in the database. Neutralizing antibodies (NAbs) against the European (D614G) strain and the Omicron BA.1 variant were assessed up to 28 days after the first booster dose. A case-control analysis was performed for the 252 participants who were followed up in 2022, during the Omicron waves.
Results: From January to October 2022, 78/252 (31%) had a documented symptomatic breakthrough infection after full vaccination: 21/117 (18%) in those who had been infected before vaccination vs. 57/135 (42%) in those who had not. In a multivariate logistic regression model, factors associated with a lower risk of breakthrough infection were older age, a higher number of booster doses, and higher levels of Omicron BA.1 NAb titers in adults with infection before vaccination, but not in those without prior infection.
Conclusion: Our results highlight the need to consider immune markers of protection in association with infection and vaccination history.
Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2024 The Author(s). Published by Elsevier Masson SAS.. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: